A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy

References

• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation20021063143342112485966
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation200411022723915249516
   PubMed Web of Science ®Google Scholar
• JonesPHStatins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy optionsAm Heart J2004148S9S1315211327
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• AshenMDBlumenthalRSLow HDL cholesterol levelsN Engl J Med20053531252126016177251
   PubMed Web of Science ®Google Scholar
• BrunzellJDHypertriglyceridemiaN Engl J Med20073571009101717804845
   PubMed Web of Science ®Google Scholar
• FarnierMUpdate on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribingVasc Health Risk Manag20084991100019183747
   PubMedGoogle Scholar
• DavidsonMHArmaniAMcKenneyJMJacobsonTASafety considerations with fibrate therapyAm J Cardiol200799 Suppl3C18C
   PubMed Web of Science ®Google Scholar
• YangLPHKeatingGMFenofibric acid: in combination therapy in the treatment of mixed dyslipidemiaAm J Cardiovasc Drugs2009940140919929038
   PubMed Web of Science ®Google Scholar
• OlssonAGMcTaggartFRazaARosuvastatin: a highly effective new HMG-CoA reductase inhibitorCardiovasc Drug Rev20022030332812481202
   PubMed Web of Science ®Google Scholar
• ShepherdJHunninghakeDBBarterPMcKenneyJMHutchinsonHGGuidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin and simvastatin for achieving lipid-lowering goalsAm J Cardiol2003915A11C17C
   Web of Science ®Google Scholar
• McKenneyJMEfficacy and safety of rosuvastatin in treatment of dyslipidemiaAm J Health Syst Pharm2005621033104715901588
   PubMed Web of Science ®Google Scholar
• FilippatosTMilionisHJTreatment of hyperlipidemia with fenofibrate and related fibratesExpert Opin Investig Drugs20081715991614
   PubMed Web of Science ®Google Scholar
• ChengJWRosuvastatin in the management of hyperlipidemiaClin Ther2004261368138715531000
   PubMed Web of Science ®Google Scholar
• Crestor (rosuvastatin calcium) Prescribing informationAstraZeneca200910 URL: http://www1.astrazeneca-us.com/pi/crestor.pdfAccessed Feb 11, 2010
   Google Scholar
• Tricor (fenofibrate) Prescribing informationAbbott200812 URL: http://www.rxabbott.com/pdf/tricorpi.pdfAccessed Feb 10, 2010
   Google Scholar
• Trilipix (fenofibric acid) Prescribing informationAbbott200812 URL: http://www.rxabbott.com/pdf/trilipix_pi.pdfAccessed Feb 10, 2010
   Google Scholar
• DavidsonMHRobinsonJGSafety of aggressive lipid managementJ Am Coll Cardiol2007491753176217466224
   PubMed Web of Science ®Google Scholar
• SchneckDWBirminghamBKZalikowskiJAThe effect of gemfibrozil on the pharmacokinetics of rosuvastatinClin Pharmacol Ther20047545546315116058
   PubMed Web of Science ®Google Scholar
• PrueksaritanontTTangCQiuYMuLSubramanianRLinJHEffects of fibrates on metabolism of statins in human hepatocytesDrug Metab Dispos2002301280128712386136
   PubMed Web of Science ®Google Scholar
• MartinPDDaneALSchneckDWWarwickMJAn open-label randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteersClin Ther20032545947112749507
   PubMed Web of Science ®Google Scholar
• ZhuTAwniWMHosmaneBABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humansJ Clin Pharmacol200949637118952910
   PubMed Web of Science ®Google Scholar
• DurringtonPNTuomilehtoJHamanAKallendDSmithKRosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemiaDiabetes Res Clin Pract20046413715115063607
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHKashyapMLEfficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 studyAtherosclerosis200920120821518996523
   PubMed Web of Science ®Google Scholar
• JonesPHBaysHEDavidsonMDEvaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statinsClin Drug Invest200828625634
   PubMed Web of Science ®Google Scholar
• BaysHEJonesPHMohiuddinSMLong-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemiaJ Clin Lipidology20082426435
   PubMed Web of Science ®Google Scholar
• GoldbergACBaysHEBallanytneCMEfficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemiaAm J Cardiol200910351552219195513
   PubMed Web of Science ®Google Scholar
• ModiuddinSMPepineCJKellyMTEfficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3 randomized, controlled studyAm Heart J200915719520319081418
   PubMed Web of Science ®Google Scholar
• KipnesMSRothEMRhyneJMYear two assessment of fenofibric acid and moderate-dose statin combinationClin Drug Investig2010305161
   PubMed Web of Science ®Google Scholar
• RothEMRosensonRSCarlsonDMA phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemiaJ Am Coll Cardiol200953 Suppl A208
   Web of Science ®Google Scholar
• MuscariAPudduGMPudduPLipid-lowering drugs: are adverse effects predictable and reversible?Cardiology20029711512112077562
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHReporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any StatinAm J Cardiol20059512012215619408
   PubMed Web of Science ®Google Scholar
• IrelandJHEggertCHArendtCJWilliamsAWRhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrateAnn Intern Med200514294995015941707
   PubMed Web of Science ®Google Scholar
• DedhiaVMunsiSCMyopathy Caused by a Combination Rosuvastatin and FenofibrateJ Assoc Physicians India20075515215317571748
   PubMedGoogle Scholar
• HouRGoldbergACLowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safetyEndocrinol Metab Clin North Am200938799719217513
   PubMed Web of Science ®Google Scholar